Chipscreen Biosciences, Ltd.

This early-stage study is testing a new oral drug called CS23546 in about 156 adults with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Resear…

This study tests whether a combination of three drugs (tucidinostat, sintilimab, and bevacizumab) can help people with a specific type of advanced colorectal cancer (MSS/pMMR) who have already tried at least two standard treatments. About 430 adults aged 18 to 75 will be randomly…

This phase 3 trial is testing whether adding the targeted drug tucidinostat to standard CHOP chemotherapy helps people with a rare form of lymphoma called peripheral T-cell lymphoma with TFH phenotype. About 224 newly diagnosed adults will receive either tucidinostat or a placebo…

This study tests an experimental capsule called CS32582 in adults with moderate-to-severe plaque psoriasis. The trial has two parts: a short 4-week dose-finding phase and a longer 12-week phase to see how well the drug clears skin and whether it is safe. About 220 participants wi…